VRDN:NSD-Viridian Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 20.07

Change

-0.12 (-0.59)%

Market Cap

USD 1.41B

Volume

1.75M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+5.83 (+1.45%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+14.04 (+1.96%)

USD 78.92B
ARGX argenx NV ADR

+3.25 (+0.50%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+2.80 (+1.20%)

USD 30.22B
MRNA Moderna Inc

+4.96 (+11.65%)

USD 16.10B
UTHR United Therapeutics Corporatio..

+6.94 (+1.95%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.29 (+1.13%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.69 (+3.95%)

USD 13.43B
INCY Incyte Corporation

+1.28 (+1.78%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.83 (+1.24%)

USD 12.74B

ETFs Containing VRDN

BBC Virtus LifeSci Biotech Cl.. 0.89 % 0.79 %

-0.06 (-0.23%)

USD 8.55M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.69% 48% F 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.69% 48% F 69% C-
Trailing 12 Months  
Capital Gain -12.24% 59% D- 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.24% 59% D- 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.42% 56% F 59% D-
Dividend Return 8.42% 56% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.61% 69% C- 43% F
Risk Adjusted Return 18.88% 75% C 51% F
Market Capitalization 1.41B 84% B 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector